828 related articles for article (PubMed ID: 12945718)
1. Lupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as measured by the systemic lupus erythematosus disease activity index (SLEDAI) and disease damage.
Brunner HI; Jones OY; Lovell DJ; Johnson AM; Alexander P; Klein-Gitelman MS
Lupus; 2003; 12(8):600-6. PubMed ID: 12945718
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
Groot N; Shaikhani D; Teng YKO; de Leeuw K; Bijl M; Dolhain RJEM; Zirkzee E; Fritsch-Stork R; Bultink IEM; Kamphuis S
Arthritis Rheumatol; 2019 Feb; 71(2):290-301. PubMed ID: 30152151
[TBL] [Abstract][Full Text] [Related]
3. European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus.
Brunner HI; Silverman ED; Bombardier C; Feldman BM
Arthritis Rheum; 2003 Jun; 49(3):335-41. PubMed ID: 12794788
[TBL] [Abstract][Full Text] [Related]
4. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
[TBL] [Abstract][Full Text] [Related]
5. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus.
Brunner HI; Gladman DD; Ibañez D; Urowitz MD; Silverman ED
Arthritis Rheum; 2008 Feb; 58(2):556-62. PubMed ID: 18240232
[TBL] [Abstract][Full Text] [Related]
6. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).
Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Catoggio LJ; Drenkard C; Sarano J; Berbotto GA; Borba EF; Sato EI; Tavares Brenol JC; Uribe O; Ramirez Gómez LA; Guibert-Toledano M; Massardo L; Cardiel MH; Silveira LH; Chacón-Diaz R; Alarcón GS; Pons-Estel BA;
Ann Rheum Dis; 2017 Dec; 76(12):2071-2074. PubMed ID: 28939626
[TBL] [Abstract][Full Text] [Related]
7. Correlation between the Modified Systemic Lupus Erythematosus Disease Activity Index 2000 and the European Consensus Lupus Activity Measurement in juvenile systemic lupus erythematosus.
Sato JO; Corrente JE; Saad-Magalhães C
Lupus; 2016 Nov; 25(13):1479-1484. PubMed ID: 27230556
[TBL] [Abstract][Full Text] [Related]
8. Assessment of clinical manifestations, disease activity and organ damage in 996 Korean patients with systemic lupus erythematosus: comparison with other Asian populations.
Joo YB; Bae SC
Int J Rheum Dis; 2015 Feb; 18(2):117-28. PubMed ID: 25524656
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage.
Brunner HI; Silverman ED; To T; Bombardier C; Feldman BM
Arthritis Rheum; 2002 Feb; 46(2):436-44. PubMed ID: 11840446
[TBL] [Abstract][Full Text] [Related]
10. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus.
Ruiz-Irastorza G; Egurbide MV; Martinez-Berriotxoa A; Ugalde J; Aguirre C
Lupus; 2004; 13(12):900-5. PubMed ID: 15645743
[TBL] [Abstract][Full Text] [Related]
11. Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies.
Descloux E; Durieu I; Cochat P; Vital Durand D; Ninet J; Fabien N; Cimaz R
Rheumatology (Oxford); 2008 Feb; 47(2):183-7. PubMed ID: 18160418
[TBL] [Abstract][Full Text] [Related]
12. Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study.
Hanly JG; Urowitz MB; O'Keeffe AG; Gordon C; Bae SC; Sanchez-Guerrero J; Romero-Diaz J; Clarke AE; Bernatsky S; Wallace DJ; Ginzler EM; Isenberg DA; Rahman A; Merrill JT; Petri M; Fortin PR; Gladman DD; Fessler BJ; Alarcón GS; Bruce IN; Dooley MA; Steinsson K; Khamashta MA; Ramsey-Goldman R; Manzi S; Sturfelt GK; Nived O; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Aranow C; Mackay M; Ruiz-Irastorza G; Kalunian KC; Lim SS; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Theriault C; Thompson K; Farewell V
Arthritis Rheum; 2013 Nov; 65(11):2887-97. PubMed ID: 24166793
[TBL] [Abstract][Full Text] [Related]
13. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
Mok CC; Ho LY; Cheung MY; Yu KL; To CH
Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
[TBL] [Abstract][Full Text] [Related]
14. Anti-dsDNA titre in female systemic lupus erythematosus patients: relation to disease manifestations, damage and antiphospholipid antibodies.
Gheita TA; Abaza NM; Hammam N; Mohamed AAA; El-Gazzar II; Eissa AH
Lupus; 2018 Jun; 27(7):1081-1087. PubMed ID: 29460701
[TBL] [Abstract][Full Text] [Related]
15. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort.
Mikdashi J; Handwerger B
Rheumatology (Oxford); 2004 Dec; 43(12):1555-60. PubMed ID: 15342927
[TBL] [Abstract][Full Text] [Related]
16. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
[TBL] [Abstract][Full Text] [Related]
17. Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre.
Hill DD; Eudy AM; Egger PJ; Fu Q; Petri MA
Lupus Sci Med; 2021 Apr; 8(1):. PubMed ID: 33832976
[TBL] [Abstract][Full Text] [Related]
18. Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa.
Lewandowski LB; Schanberg LE; Thielman N; Phuti A; Kalla AA; Okpechi I; Nourse P; Gajjar P; Faller G; Ambaram P; Reuter H; Spittal G; Scott C
Lupus; 2017 Feb; 26(2):186-194. PubMed ID: 27488473
[TBL] [Abstract][Full Text] [Related]
19. Outcome measures to be used in clinical trials in systemic lupus erythematosus.
Strand V; Gladman D; Isenberg D; Petri M; Smolen J; Tugwell P
J Rheumatol; 1999 Feb; 26(2):490-7. PubMed ID: 9972993
[TBL] [Abstract][Full Text] [Related]
20. Severe vitamin D deficiency increases the risk for moderate to severe disease activity in Chinese patients with SLE.
Gao CC; Liu SY; Wu ZZ; Li TF; Gao GM; Liu ZS; Zheng ZH
Lupus; 2016 Oct; 25(11):1224-9. PubMed ID: 26921268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
